Strength
400; 100 mg/1; mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958220101
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Last Updated
4/22/2026
Active Ingredients
SOFOSBUVIR; VELPATASVIRApproval Type
New Drug (NDA)
FDA Application
NDA208341On Market Since
6/28/2016
Pharmacological Classes
Breast Cancer Resistance Protein Inhibitors
Hepatitis C Virus NS5A Inhibitor
Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Organic Anion Transporting Polypeptide 1B1 Inhibitors
Organic Anion Transporting Polypeptide 1B3 Inhibitors
Organic Anion Transporting Polypeptide 2B1 Inhibitors
P-Glycoprotein Inhibitors
RNA Replicase Inhibitors
Related Drugs
Same classification
MYRBETRIQ ER 8 MG/ML SUSP
Brand
00469502099•Astellas Pharma US, Inc.
$2.2097
per ML
ZONISADE 100 MG/5 ML ORAL SUSP
Brand
52652800101•Azurity Pharmaceuticals Inc.
$2.7530
per ML
NEORAL 25 MG GELATIN CAPSULE
Brand
00078024615•Novartis Pharmaceuticals Corporation
$2.8879
per EA
KALETRA 80 MG-20 MG/ML SOLN
Brand
00074395646•AbbVie Inc.
$3.1186
per ML
SANDIMMUNE 25 MG CAPSULE
Brand
00078024015•Novartis Pharmaceuticals Corporation
$4.3773
per EA
BRILINTA 90 MG TABLET
Brand
00186077739•AstraZeneca Pharmaceuticals LP
$7.4222
per EA
BRILINTA 90 MG TABLET
Brand
00186077760•AstraZeneca Pharmaceuticals LP
$7.4222
per EA
BRILINTA 60 MG TABLET
Brand
00186077660•AstraZeneca Pharmaceuticals LP
$7.4281
per EA
KALETRA 200-50 MG TABLET
Brand
00074401412•AbbVie Inc.
$8.3041
per EA
KALETRA 200-50 MG TABLET
Brand
00074679922•AbbVie Inc.
$8.3041
per EA